BIOGNOSYS
15.3.2022 14:02:09 CET | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.
Proteome editing with TPD is a new frontier of medicine, aimed at expanding the druggable proteome. Biognosys’ TrueSignature™ platform uniquely offers high-precision proteomic panels that provide actionable insights based on highly specific and sensitive, absolute quantification of pharmacodynamic and efficacy biomarkers. These custom panels allow Kymera to monitor and quantify protein degradation. The ease of transferability of the assays — from early discovery, across preclinical evaluation, to clinical development — enables integration into all stages of Kymera’s drug development process . The panels are developed and performed at Biognosys’ state-of-the-art facility, the largest high-end, GLP certified and GCP compliant mass spectrometry laboratory worldwide for large-scale proteomics contract research.
“Kymera’s novel approach to targeted protein degradation is a great example of the power of proteomics-enabled drug development,” said Kristina Beeler, Ph.D., Chief Business Officer of Biognosys . “We are glad to see the impact our TrueSignature platform is having, not only on the advancement of Kymera’s clinical trial programs, but also on patients’ lives.”
The current partnership between Kymera and Biognosys builds upon the longstanding scientific relationship between the two companies across early R&D, preclinical, and clinical settings across oncology and inflammation.
“Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications,” said Nello Mainolfi, Ph.D., Co-Founder, President and CEO, Kymera Therapeutics . “The company’s high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs.”
About TrueSignature™
The Biognosys TrueSignature™ platform provides high-precision customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring.
Parallel Reaction Monitoring mass-spectrometry powers the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature™ panels offer an unprecedented level of multiplexing, enabling the simultaneous absolute quantification of up to 100 proteins.
TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies guide the choice of proteins in the custom panel. The measurements are performed with unprecedented speed and throughput at Biognosys' state-of-the-art facility, the world's largest high-end GLP-certified and GCP-compliant mass spectrometry laboratory. For more information, visit truesignature.bio
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers, and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CloudInteract and Red Kite Launch Joint Delivery Partnership for Agentic AI Voice on Amazon Connect and Pega4.6.2026 14:19:00 CEST | Press release
This expert partnership takes agentic voice deployments for customers from quarters to weeks; a demonstrator can be seen at PegaWorld 2026 CloudInteract, the Amazon Connect and agentic AI specialist, and Red Kite, the Pega delivery partner, today announced a joint delivery partnership to bring autonomous AI voice agents to enterprises using the Pega and Amazon Connect platforms. The partnership debuts a working solution on Amazon Connect, Amazon Bedrock, that can be seen at PegaWorld® in Las Vegas, 7–9 June 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604645983/en/ Initial use cases span healthcare, financial services, insurance, government, and BPO. The companies will demonstrate a healthcare appointment booking call at PegaWorld, but the same architecture applies to any regulated environment where AI interactions must be executed within governed workflows, using real-time customer context, policy, and decisionin
Mobix Labs to Acquire U.S.-Built Drone Manufacturer Vision Aerial, Expanding Into Global Drone and Aerial Intelligence Markets4.6.2026 14:00:00 CEST | Press release
Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a binding Letter of Intent to acquire Vision Aerial, Inc., a Montana-based manufacturer of American-built drones trusted in national security, government, energy, public safety, and critical infrastructure operations. The acquisition expands Mobix Labs into a fast-growing global market and marks the latest step in its previously announced strategy to grow through targeted, mission-critical acquisitions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604386607/en/ Built in America. Trusted Where Performance Matters. Founded in 2013, Vision Aerial designs, manufactures, and supports rugged drone systems built for the most demanding field operations. Each aircraft can carry swappable cameras and sensors—from high-resolution and heat-sensing thermal cameras to laser-based 3-D mapping and gas-leak detection—allowing one platform to support multiple mission prof
Visa and Brale Explore Private Stablecoin Settlement for Institutional Payments4.6.2026 14:00:00 CEST | Press release
Proof of concept will test how privacy-enabled blockchain infrastructure can support secure, scalable settlement for institutional payment flows Visa (NYSE: V) today announced a collaboration with Brale to explore stablecoin-based settlement using SBC, a U.S. dollar-backed stablecoin issued by Brale, on the Canton Network. The proof of concept will evaluate how privacy-enabled blockchain infrastructure can support faster, more programmable settlement while helping financial institutions and payment companies maintain control over the visibility of sensitive settlement transaction data. Visa began enabling stablecoin settlement in 2021 and continues to expand its capabilities, allowing VisaNet obligations to be settled using supported stablecoins. A central focus of this collaboration is the Canton Network’s privacy architecture. As stablecoin adoption grows, financial institutions are assessing how they can use blockchain-based settlement while meeting strict privacy and compliance req
The Open Group Publishes Industrial Advanced Nuclear™ Consortium’s Inaugural Application Scenarios Whitepaper4.6.2026 14:00:00 CEST | Press release
The Whitepaper provides a blueprint on how advanced nuclear energy can be deployed across heavy industry The Open Group, the vendor-neutral technology standards organization, today announced the publication of the Industrial Advanced Nuclear™ Consortium (IANC) Application Scenarios Whitepaper, setting out how advanced nuclear technologies can be deployed to deliver reliable, low‑carbon heat and power across heavy industry. The Whitepaper, driven by IANC, an industrial end-user-driven organization, represents a significant step forward in the role of nuclear energy in relation to energy transition. Outlining real-world use cases where Small Modular Reactors (SMRs) and Micro Modular Reactors (MMRs) could be integrated directly into industrial operations, it focuses on sectors that are amongst the most difficult to decarbonize, including: Offshore energy Refining and petrochemicals Mining Energy‑intensive manufacturing. Developed by leading industrial end users, the Whitepaper provides a
Kinaxis Unveils 2026 Customer Award Winners at Kinexions in Las Vegas4.6.2026 13:00:00 CEST | Press release
Global supply chain leaders recognized for delivering bold innovation, agility, and measurable impact Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the winners of its 2026 Customer Awards. Now in their eighth year, these awards were celebrated live at Kinexions North America, the flagship premiere global conference hosted by Kinaxis, bringing together supply chain leaders from around the world. The annual awards spotlight organizations and individuals who are redefining what’s possible in modern supply chains. The winners are driving innovation, responding with agility, and delivering real business results with the Kinaxis Maestro™ platform. The awards recognized seven leading companies including Reckitt, General Motors, Lupin, Jabil, and Cardinal Health among the full list of winners. Additionally, Praveen Vasudevan (Bio-Rad Laboratories) received the champion award for their industry contributions. “Kinexions is where the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom